La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Mega Lifesciences Crescita futura

Future criteri di controllo 2/6

Mega Lifesciences prevede che gli utili e i ricavi cresceranno rispettivamente di 11.8% e 5% all'anno. Si prevede che l'EPS crescerà di 11.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 25% in 3 anni.

Informazioni chiave

11.8%

Tasso di crescita degli utili

11.5%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	17.1%
Tasso di crescita dei ricavi	5.0%
Rendimento futuro del capitale proprio	25.0%
Copertura analitica	Good
Ultimo aggiornamento	16 Aug 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

SET:MEGA - Stime future degli analisti e dati finanziari passati (THB Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	17,847	2,793	2,356	2,758	5
12/31/2025	16,688	2,566	2,402	2,762	6
12/31/2024	16,179	2,606	2,392	2,880	3
6/30/2024	15,685	1,999	2,400	2,667	N/A
3/31/2024	15,718	2,017	1,915	2,166	N/A
12/31/2023	15,716	1,993	1,633	1,926	N/A
9/30/2023	15,442	1,919	2,297	2,583	N/A
6/30/2023	15,693	2,042	1,773	2,035	N/A
3/31/2023	15,634	2,081	1,798	2,077	N/A
12/31/2022	15,727	2,242	1,684	1,997	N/A
9/30/2022	15,116	2,338	1,327	1,596	N/A
6/30/2022	15,061	2,292	1,852	2,091	N/A
3/31/2022	14,724	2,227	1,800	2,025	N/A
12/31/2021	14,172	1,947	2,567	2,727	N/A
9/30/2021	14,395	1,878	2,302	2,474	N/A
6/30/2021	13,775	1,607	2,289	2,485	N/A
3/31/2021	12,809	1,406	1,932	2,178	N/A
12/31/2020	12,613	1,393	1,374	1,629	N/A
9/30/2020	12,168	1,348	1,487	1,815	N/A
6/30/2020	11,642	1,288	1,122	1,508	N/A
3/31/2020	11,655	1,205	1,271	1,707	N/A
12/31/2019	11,164	1,139	954	1,495	N/A
9/30/2019	10,950	1,163	468	1,406	N/A
6/30/2019	10,712	1,136	275	1,163	N/A
3/31/2019	10,569	1,203	-158	657	N/A
12/31/2018	10,284	1,206	158	910	N/A
9/30/2018	10,147	1,183	429	747	N/A
6/30/2018	9,937	1,175	569	929	N/A
3/31/2018	9,829	1,178	N/A	1,150	N/A
12/31/2017	9,624	1,113	N/A	927	N/A
9/30/2017	9,514	1,023	N/A	967	N/A
6/30/2017	9,282	945	N/A	1,081	N/A
3/31/2017	8,968	873	N/A	1,237	N/A
12/31/2016	8,828	795	N/A	1,250	N/A
9/30/2016	8,514	771	N/A	1,174	N/A
6/30/2016	8,226	756	N/A	920	N/A
3/31/2016	8,115	703	N/A	764	N/A
12/31/2015	7,966	696	N/A	609	N/A
9/30/2015	7,775	675	N/A	825	N/A
6/30/2015	7,862	634	N/A	803	N/A
3/31/2015	7,851	598	N/A	581	N/A
12/31/2014	7,749	548	N/A	614	N/A
9/30/2014	7,620	474	N/A	406	N/A
6/30/2014	7,422	516	N/A	416	N/A
3/31/2014	7,226	567	N/A	473	N/A
12/31/2013	7,055	624	N/A	466	N/A
9/30/2013	6,812	593	N/A	380	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di MEGA ( 11.8% all'anno) è superiore al tasso di risparmio ( 2% ).

Guadagni vs Mercato: Si prevede che gli utili di MEGA ( 11.8% all'anno) cresceranno più lentamente rispetto al mercato TH ( 15% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di MEGA cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di MEGA ( 5% all'anno) crescerà più lentamente rispetto al mercato TH ( 6.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MEGA ( 5% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di MEGA sarà elevato tra 3 anni ( 25 %)

Mega Lifesciences Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita